U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07600164) titled 'Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer' on May 07.
Brief Summary: Given that pyrotinib has been proven to exert significant efficacy against HER2-positive advanced breast cancer in multiple Phase III studies, and the novel ADC drug disitamab vedotin has demonstrated potent anti-tumor activity, there remains insufficient real-world data on their sequential administration. This multicenter, prospective real-world study plans to enroll 500 patients with HER2-positive advanced breast cancer receiving first-line or second-line treatment. It aims to evaluate the efficacy and safety of sequ...